{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T13:34:22Z","timestamp":1772112862990,"version":"3.50.1"},"reference-count":34,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T00:00:00Z","timestamp":1723852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Dermatology, Paediatric Dermatology and Oncology Clinic, Medical University of Lodz, Poland","award":["503\/1-064-01\/503-11-001"],"award-info":[{"award-number":["503\/1-064-01\/503-11-001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Psoriasis is a chronic, multisystemic, inflammatory disease affecting approximately 1% of children and significantly reducing their health-related quality of life. Etanercept is a biologic fusion protein-blocking TNF-\u03b1 and belongs to one of the biologics used among the children population. The purpose of this study was to assess the effectiveness and safety profile of etanercept in paediatric patients with plaque-type psoriasis. Material and methods: The outcome of the treatment was evaluated based on Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and Children\u2019s Dermatology Life Quality Index (CDLQI). Achievement of at least PASI75 at week 16 was assessed as an adequate response to therapy, which was the primary endpoint. Results: Forty-three paediatric patients were included in the study, 24 females and 19 males. The average age at inclusion into our study was 13 years. At baseline, the mean PASI score, BSA, and CDLQI were 16.3 \u00b1 6.5, 22.3 \u00b1 12.2%, and 17.4 \u00b1 5.3, respectively. At week 16, 90.7% of patients achieved PASI 50, 79.1% achieved PASI 75, and 46.5% attained PASI 90. There was also a decrease in mean BSA and CDLQI values to 3.5 \u00b1 3.8 and 5.4 \u00b1 5.7, respectively. Conclusions: Etanercept proved to be effective, safe, and well-tolerated among the paediatric population with psoriasis.<\/jats:p>","DOI":"10.3390\/jcm13164858","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T06:41:31Z","timestamp":1724049691000},"page":"4858","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness and Safety of Etanercept in Paediatric Patients with Plaque-Type Psoriasis: Real-World Evidence"],"prefix":"10.3390","volume":"13","author":[{"given":"Joanna","family":"Narbutt","sequence":"first","affiliation":[{"name":"Department of Dermatology, Paediatric Dermatology and Oncology, Medical University of Lodz, 90-419 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zofia","family":"Jakubczak","sequence":"additional","affiliation":[{"name":"Students\u2019 Scientific Association of Experimental, Clinical and Surgical Dermatology, Medical University of Lodz, 91-347 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulina","family":"Wasiewicz-Ciach","sequence":"additional","affiliation":[{"name":"Students\u2019 Scientific Association of Experimental, Clinical and Surgical Dermatology, Medical University of Lodz, 91-347 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Wojtania","sequence":"additional","affiliation":[{"name":"Students\u2019 Scientific Association of Experimental, Clinical and Surgical Dermatology, Medical University of Lodz, 91-347 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Krupa","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Paediatric Dermatology and Oncology, Medical University of Lodz, 90-419 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Sobolewska-Sztychny","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Paediatric Dermatology and Oncology, Medical University of Lodz, 90-419 Lodz, Poland"},{"name":"Laboratory of Autoinflammatory, Genetic and Rare Skin Disorders, Department of Dermatology, Pediatric Dermatology and Oncology, Medical University of Lodz, 91-347 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Ci\u0105\u017cy\u0144ska","sequence":"additional","affiliation":[{"name":"Laboratory of Autoinflammatory, Genetic and Rare Skin Disorders, Department of Dermatology, Pediatric Dermatology and Oncology, Medical University of Lodz, 91-347 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Ko\u0142t-Kami\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, 35-055 Rzeszow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5573-1754","authenticated-orcid":false,"given":"Adam","family":"Reich","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, 35-055 Rzeszow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Skibi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Paediatric Dermatology and Oncology, Medical University of Lodz, 90-419 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Lesiak","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Paediatric Dermatology and Oncology, Medical University of Lodz, 90-419 Lodz, Poland"},{"name":"Laboratory of Autoinflammatory, Genetic and Rare Skin Disorders, Department of Dermatology, Pediatric Dermatology and Oncology, Medical University of Lodz, 91-347 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,17]]},"reference":[{"key":"ref_1","first-page":"626","article-title":"Psoriasis","volume":"87","author":"Weigle","year":"2013","journal-title":"Am. Fam. Physician"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Diotallevi, F., Simonetti, O., Rizzetto, G., Molinelli, E., Radi, G., and Offidani, A. (2022). Biological treatments for paediatric psoriasis: State of the art and future perspectives. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911128"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"key":"ref_4","first-page":"S19","article-title":"Parental stress and quality of life in chronic childhood dermatoses: A review","volume":"14","author":"Datta","year":"2021","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_5","first-page":"169","article-title":"Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis","volume":"8","author":"Kivelevitch","year":"2014","journal-title":"Biologics."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/archderm.141.12.1537","article-title":"Prevalence and treatment of psoriasis in the United Kingdom: A population-based study","volume":"141","author":"Gelfand","year":"2005","journal-title":"Arch. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2133.2009.09593.x","article-title":"Epidemiology and comorbidity of psoriasis in children","volume":"162","author":"Augustin","year":"2010","journal-title":"Br. J. Dermat."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1080\/09546630902911847","article-title":"Epidemiology and prescribed treatments in childhood psoriasis: A survey among medical professionals","volume":"20","author":"Seyger","year":"2009","journal-title":"J. Dermatol. Treat."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","article-title":"Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections","volume":"80","author":"Kaushik","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Kelly, K.A., Balogh, E.A., Kaplan, S.G., and Feldman, S.R. (2021). Skin disease in children: Effects on quality of life, stigmatization, bullying, and suicide risk in pediatric acne, atopic dermatitis, and psoriasis patients. Children, 8.","DOI":"10.3390\/children8111057"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.5114\/dr.2021.110913","article-title":"Psoriasis in children. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 1","volume":"108","author":"Narbutt","year":"2021","journal-title":"Dermatol. Rev.\/Przegl. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5114\/dr.2021.111962","article-title":"Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 2","volume":"108","author":"Narbutt","year":"2021","journal-title":"Dermatol. Rev.\/Przegl. Dermatol."},{"key":"ref_13","unstructured":"(2023, March 01). B.47 Drug Programme, Available online: https:\/\/www.gov.pl\/web\/zdrowie\/obwieszczenia-ministra-zdrowia-lista-lekow-refundowanych."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.crohns.2013.01.009","article-title":"Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease","volume":"7","author":"Mocci","year":"2013","journal-title":"J. Crohns Colitis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa066886","article-title":"Etanercept treatment for children and adolescents with plaque psoriasis","volume":"358","author":"Paller","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2019.08.049","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients","volume":"82","author":"Menter","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1080\/09546634.2022.2059051","article-title":"Managing pediatric psoriasis: Update on treatments and challenges-a review","volume":"33","author":"Hebert","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_18","unstructured":"(2023, July 24). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/erelzi."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","article-title":"Definition of treatment goals for moderate to severe psoriasis: A European consensus","volume":"303","author":"Mrowietz","year":"2011","journal-title":"Arch. Dermatol. Res."},{"key":"ref_20","unstructured":"(2023, July 24). Available online: https:\/\/www.jakicentyl.pl\/."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2133.2011.10583.x","article-title":"Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta-analysis of randomized controlled trials","volume":"166","author":"Reich","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaad.2021.02.057","article-title":"Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data","volume":"85","author":"Shear","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.jval.2015.07.010","article-title":"Long-Term Efficacy of Etanercept for Plaque-Type Psoriasis and Estimated Cost in Daily Clinical Practice","volume":"18","author":"Paradela","year":"2015","journal-title":"Value Health"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1468-3083.2008.03063.x","article-title":"Etanercept: Efficacy and safety","volume":"23","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/11310770-000000000-00000","article-title":"Efficacy and safety of etanercept in psoriasis after switching from other treatments: An observational study","volume":"10","author":"Mazzotta","year":"2009","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/1203475418755998","article-title":"OBSERVE-5: Comparison of Etanercept-Treated Psoriasis Patients From Canada and the United States","volume":"22","author":"Papp","year":"2018","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/09546634.2017.1364692","article-title":"Effectiveness of etanercept in children with plaque psoriasis in real practice: A one-year multicenter retrospective study","volume":"29","author":"Guarneri","year":"2018","journal-title":"J. Dermatol. Treat."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1684\/ejd.2023.4404","article-title":"A long-term, prospective, observational cohort study of the safety and effectiveness of etanercept for the treatment of patients with paediatric psoriasis in a naturalistic setting","volume":"33","author":"Gu","year":"2023","journal-title":"Eur. J. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000343605","article-title":"Efficacy and safety of clinical use of etanercept for the treatment of moderate-to-severe psoriasis in Spain: Results of a multicentric prospective study at 12 months follow-up","volume":"225","author":"Puig","year":"2012","journal-title":"Dermatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1365-2133.2011.10584.x","article-title":"Long-term efficacy of etanercept for psoriasis in daily practice","volume":"166","author":"Driessen","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/art.23427","article-title":"Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis","volume":"58","author":"Lovell","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/art.21885","article-title":"Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis","volume":"54","author":"Lovell","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis","volume":"342","author":"Lovell","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaad.2015.09.056","article-title":"Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis","volume":"74","author":"Paller","year":"2016","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/16\/4858\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:38:06Z","timestamp":1760110686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/16\/4858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,17]]},"references-count":34,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["jcm13164858"],"URL":"https:\/\/doi.org\/10.3390\/jcm13164858","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,17]]}}}